Skip Navigation
 
  • Contact Us
  • Search Toggle
  • Visit us on Twitter
  • Visit us on LinkedIn
OnKure Therapeutics logo
  • About Us
    • Our Company
    • Our Team
      • Management
      • Board of Directors
      • Scientific Advisors
      • Investors
      • Collaborators
  • Our Expertise
  • Pipeline
    • Our Pipeline
    • OKI-179
    • Our Targets
  • News & Publications
    • Press Releases
    • Publications
  • Careers
    • Join Our Team
    • Job Opportunities
  • Contact Us
OnKure News & Publications
News & Publications
Scroll Down

Publications

  • April, 2022

    OKI-179

    The class I-targeting, oral HDAC inhibitor OKI-179 increases tumor regressions when combined with the MEK inhibitor binimetinib in models of NRAS melanoma

  • March, 2022

    OKI-179

    Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

  • August, 2021

    OKI-179

    Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms

  • October, 2020

    OKI-179

    Initial results from a phase 1 trial of OKI-179, an oral Class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors

  • October, 2020

    OKI-179

    Initial Results from a Phase 1 trial of OKI-179, an Oral Class 1-selective Depsipeptide HDCA Inhibitor, in Patients with Advanced Solid Tumors

  • January, 2020

    OKI-179

    HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma

  • October, 2019

    OKI-179

    OKI-179, A 1st in Class, Orally Administered HDAC Inhibitor with a Romidepsin-like Profile

  • August, 2019

    OKI-179

    Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas

  • February, 2019

    OKI-179

    Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

ONKure Therapeutics logo white

Corporate Office

6707 Winchester Circle
Suite 400
Boulder, Colorado 80301

Tel: (720) 307-2892

Contact Us

©2023 OnKure, Inc. All Rights Reserved.

  • Site Map
  • Privacy Policy
  • Terms of Use